6 March 2024
LungLife AI Inc
(the "Company" or "LungLife")
Posting of Circular
And Notice of Special Meeting
LungLife AI Inc (AIM: LLAI), a developer of clinical diagnostic solutions for the early detection of lung cancer, confirms that further to the announcements on 4 and 5 March 2024, a Circular in connection with the Placing and Subscription (the "Circular"), including the Notice of Special Meeting, has today been despatched to shareholders. A copy of the Circular and Notice of Special Meeting is available on the Company's website at https://lunglifeai.com/investors/shareholder-information/.
The Special Meeting will be held at 11.00 a.m. on 21 March 2024 at Mayer Brown International LLP, at 201 Bishopsgate, London, EC2M 3AF and online by virtual link.
The Form of Proxy for use in connection with the Special Meeting should be completed and returned in accordance with the instructions thereon so as to be received by the Company's registrars, Link Group, PXS1, Central Square, 29 Wellington Street, Leeds, LS1 4DL by no later than 11.00 a.m. on 19 March 2024.
The Form of Direction for use in connection with the Special Meeting should be completed and returned in accordance with the instructions thereon so as to be received by the Company's registrars, Link Group, PXS1, Central Square, 29 Wellington Street, Leeds, LS1 4DL by no later than 11.00 a.m. on 18 March 2024.
Completion of the Form of Proxy or Form of Direction will not preclude shareholders from attending and voting in person at the Special Meeting should the so wish.
The Board believe that each of the Resolutions is in the best interest of the Company and its shareholders as a whole and unanimously recommends shareholders to vote in favour of them, as the Directors have irrevocably undertaken to do in respect of their own beneficial shareholdings, which in aggregate represent 0.17 per cent. of the Common Shares currently in issue.
Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as defined in the announcement released by the Company on 4 March 2024.
For further information please contact:
| LungLife AI, Inc. | |
| Paul Pagano, CEO | Via Walbrook PR |
| David Anderson, CFO |
|
|
|
|
| Investec Bank plc (Nominated Adviser & Joint Broker) | Tel: +44 (0)20 7597 5970 |
| Virginia Bull / Cameron MacRitchie / Lydia Zychowska | |
| | |
| Goodbody Stockbrokers UC (Joint Broker) Tom Nicholson / Cameron Duncan / William Hall
| Tel: +44 (0)20 3841 6202 |
| Walbrook PR Limited | Tel: +44 (0)20 7933 8780 |
| Paul McManus / Alice Woodings / Phillip Marriage |
About LungLife
LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit www.lunglifeai.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.